Alamar Biosciences has launched a research-use-only assay that measures five Alzheimer’s-related biomarkers from a single blood sample – consolidating tests that previously required multiple separate assays. The NULISAqpcr AD 5-plex Assay covers brain-derived phosphorylated tau 217 (BD-pTau217), neurofilament light chain (NfL), amyloid-beta 42 (Aβ42), glial fibrillary acidic protein (GFAP), and APOE4 carrier status, aligned with Alzheimer’s Association recommended guidelines.
The assay is designed to enable monitoring of amyloid and tau pathology, neurodegeneration, and inflammation in a single multiplexed format – a significant workflow improvement for researchers working on early detection and screening.
“Blood-based biomarkers are redefining Alzheimer’s research, providing an accurate, cheaper and more accessible means of establishing early diagnosis,” said Dr. Steven Williams, Alamar’s chief scientific officer.
While the assay is not women’s health-specific, the disease it targets very much is. Nearly two-thirds of Americans living with Alzheimer’s are women, and emerging research increasingly points to a link between estrogen decline during menopause and elevated Alzheimer’s risk – making earlier, more accessible diagnostic tools particularly relevant for women’s long-term health. Advances in blood-based biomarker testing could eventually help shift detection earlier into the window where intervention is most effective.
The assay is available now as a service through Alamar’s Technology Access Program.
